WASHINGTON (AP) — Biotech drugmaker Amgen Inc. spent $2.82 million lobbying the federal government during the third quarter, focusing its efforts on health care and prescription drug issues.
The Thousand Oaks, Calif.-based company's lobbying budget increased 23 percent from the second quarter, when the company spent $2.3 million. Lobbying spending was down 4 percent from $2.94 million it spent in third-quarter of 2010.
The company also lobbied on the new regulatory system for biosimilars, or copies of lucrative biotechnology drugs. The FDA previously only regulated the approval of generic drugs made from chemical compounds because it did not have a system in place for similar versions of biotech drugs, or biosimilars, which are developed using more complicated living cells. Under the health reform law of 2010, the FDA is instructed to give new biotechnology drugs 12 years of competitive protection from biosimilars. The framework was considered a major victory for Amgen and other biotech companies looking to preserve profits on their drugs. The FDA is still drafting regulations on how it will accept and review biosimilar drugs.
Amgen also lobbied on Medicare reimbursement for dialysis treatment and products, which are used by patients with failing kidneys.
The cost of dialysis services is a major concern for state and federal government officials because the vast majority of U.S. kidney disease patients receive care through the Medicare and Medicaid health systems. Medicare is the federally funded health program for seniors and the disabled. Medicaid is a jointly funded federal-state plan for low-income Americans.
In addition, Amgen lobbied on legislation related to tax rates, patents and trademarks.
Amgen makes blockbuster anemia drugs including Aranesp and Epogen. Other products include Neulasta and Neupogen, which help prevent infections in chemotherapy patients.
Along with Congress, Amgen lobbied the Centers for Medicare and Medicaid Services, according to a form filed with the House clerk's office Oct. 20.
Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
